RxDoctor Payments Data

John Clark, MD

Neurology · Fernandina Beach, FLNPI 1235166943

Payments from drug & device makers

$93,549in general payments, 2019–2025

Across 178 payments — averaging $525.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$43K
  • Teva Pharmaceuticals USA, Inc.$17K
  • Genentech USA, Inc.$13K
  • Biogen$11K
  • Sanofi$9K
  • AbbVie$292
  • plus $592 from 11 others

What the payments were for

  • Consulting fees$6,8757%
  • Speaking & faculty fees$77,85783%
  • Travel & lodging$4,7255%
  • Food & beverage$3,9014%
  • Education$1920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$93,549 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$234,382
Medicare patients
551
Services billed
16,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Plegridy PenPeginterferon Beta-1a14$115,751
LamictalLamotrigine36$59,988
NuedextaDextromethorphan Hbr/Quinidine24$41,153
Lamictal XrLamotrigine17$37,014
Ajovy AutoinjectorFremanezumab-Vfrm38$33,123
UbrelvyUbrogepant25$30,407
Aimovig AutoinjectorErenumab-Aooe38$29,010
EliquisApixaban24$24,676
Dalfampridine ErDalfampridine17$20,815
QuliptaAtogepant19$19,955
FycompaPerampanel17$19,001
GocovriAmantadine Hcl11$18,511
Nurtec OdtRimegepant Sulfate16$17,366
Levetiracetam380$13,188
Gabapentin307$9,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$292$50,36244 claims
PfizerEliquis, Nurtec Odt, Dilantin$18$49,17166 claims
Eisai Inc.Fycompa$43$19,00117 claims
MDD US Operations, LLCGocovri$23$18,51111 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$50$1,83433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →